Physician profile
Amikar Sehdev
NPI 1588891667
$13,746.21
in general payments reported to CMS, 2019-2025
64 companies · $3,783 in 2025
The $3,783 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $573 · 2021: $1,558 · 2022: $2,311 · 2023: $2,341 · 2024: $3,181 · 2025: $3,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,068 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,067.80 |
| Education | $236.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,063.10 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $880.99 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $860.03 | 2020-2025 | Imfinzi, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $760.90 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Pfizer INC. | $656.89 | 2021-2025 | |
| Genzyme Corporation | $615.44 | 2020-2025 | |
| Daiichi Sankyo INC. | $561.87 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $537.36 | 2020-2025 | Venclexta |
| Celgene Corporation | $510.27 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Amgen INC. | $485.33 | 2020-2023 | Vectibix, Xgeva, Nplate |
| Genentech USA, INC. | $483.11 | 2021-2025 | Tecentriq, Alecensa, Polivy |
| Janssen Biotech, INC. | $450.46 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Lilly USA, LLC | $435.33 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $411.37 | 2020-2024 | Vyloy, Xospata, Padcev |
| Seagen INC. | $296.26 | 2020-2023 | Adcetris |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $278.84 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Array Biopharma INC | $263.05 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $227.31 | 2021-2025 | |
| Genmab U.S., INC. | $210.13 | 2023-2025 | Tivdak, Epkinly |
| Puma Biotechnology, INC. | $210.02 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $188.19 | 2022-2024 | Ultomiris |
| Adc Therapeutics America, INC. | $187.21 | 2023-2025 | |
| Sirtex Medical INC | $179.79 | 2023 | Sir-Spheres Microspheres |
| Springworks Therapeutics, INC. | $160.71 | 2024-2025 | Ogsiveo |
| Sanofi-Aventis U.S. LLC | $154.98 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $148.97 | 2020-2023 | Imbruvica, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.24 | 2021-2025 | Gilotrif |
| Glaxosmithkline, LLC. | $141.68 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Ipsen Biopharmaceuticals, INC | $138.41 | 2020-2025 | Onivyde, Somatuline Depot |
| Rigel Pharmaceuticals, INC. | $128.04 | 2021-2025 | Rezlidhia, Gavreto, Tavalisse |
| Blueprint Medicines Corporation | $118.23 | 2020-2024 | Ayvakit |
| Emd Serono, INC. | $111.30 | 2022-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $107.66 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $106.16 | 2023-2025 | Qinlock, Romvimza |
| Eisai INC. | $106.07 | 2021-2024 | |
| Gilead Sciences, INC. | $97.09 | 2021-2024 | |
| Kyowa Kirin, INC. | $90.91 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.05 | 2021-2025 | Fruzaqla, Alunbrig |
| Karyopharm Therapeutics INC. | $80.46 | 2020-2023 | Xpovio |
| Carbofix Orthopedics INC | $80.16 | 2025 | |
| Beone Medicines USA, INC. | $73.50 | 2025 | Brukinsa, Tevimbra |
| Sobi, INC | $72.74 | 2023-2025 | |
| Stemline Therapeutics INC. | $70.03 | 2023-2024 | Orserdu |
| Mirati Therapeutics, INC. | $64.17 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $61.49 | 2020-2024 | Libtayo |
| Syndax Pharmaceuticals, INC. | $59.27 | 2025 | |
| Kite Pharma, INC. | $57.90 | 2024-2025 | Yescarta |
| Clovis Oncology, INC. | $55.67 | 2021 | |
| Geron Corporation | $52.64 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $51.60 | 2023-2025 | Zoladex, Quzyttir |
| Morphosys, US INC. | $51.07 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $43.95 | 2023-2025 | |
| Beigene USA, INC. | $43.37 | 2024-2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $31.12 | 2025 | |
| Cti Biopharma Corp. | $28.19 | 2023 | Vonjo |
| Epizyme, INC. | $21.92 | 2021 | |
| Boston Scientific Corporation | $21.59 | 2024 | |
| Azurity Pharmaceuticals, INC. | $20.12 | 2025 | Danziten |
| Amag Pharmaceuticals, INC. | $19.18 | 2021 | |
| G1 Therapeutics, INC. | $18.40 | 2021 | |
| Progenics Pharmaceuticals, INC. | $17.94 | 2024 | |
| Eusa Pharma (US) LLC | $17.61 | 2022 | |
| Pharmaessentia USA Corporation | $16.98 | 2025 | Besremi |
| Taiho Oncology, INC. | $14.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amikar Sehdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.